Berge K, Schirmer H, Øvrebotten T, Nahoui H, Gullestad L, Ingul CB, Hole T, Mo R, Larsby K, Norekvål TM, Omland T, Ørn S, Myhre PL(2025) Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF guidelines ESC Heart Fail(in press) DOI 10.1002/ehf2.15337, PubMed 40574622
Holt MF, Michelsen AE, Flø A, Khan Y, Bjørnø VK, Skjelland M, Bjerkeli V, Paus B, Escobar Kvitting JP, Halvorsen B, Wien TN, Raki M, Gullestad L, Aukrust P, Broch K, Ueland T, Gude E(2025) Hepatocyte Growth Factor: A Marker of Cardiac Function, Mortality, and Disease Subtype in Cardiac Amyloidosis JACC Adv, 4(6 Pt 1), 101828(in press) DOI 10.1016/j.jacadv.2025.101828, PubMed 40570404
Dahl TB, Quiles-Jiménez A, Broch K, Anstensrud AK, Gullestad L, Andersen GØ, Kleveland O, Øgaard J, Bjerkeli V, Rashidi A, Yang K, Holven KB, Aukrust P, Bjørås M, Huse C, Halvorsen B(2025) The N-6 methyladenosine dynamics in STEMI and the effect of IL-6 inhibition - a hypothesis generating sub-study of the ASSAIL-MI trial Front Immunol, 16, 1532325 DOI 10.3389/fimmu.2025.1532325, PubMed 40547027